Author

Ke Xiao

Washington University in St. LouisORCID 0000-0001-5260-7996Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alex T. LarssoniD· 1 shared Angela C. HirbeiD· 1 shared Belinda B. GaranaiD· 1 shared Christine A. PratilasiD· 1 shared Dana C. BorcherdingiD· 1 shared David A. LargaespadaiD· 1 shared David K. WoodiD· 1 shared Elizabeth Rono· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex T. LarssonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintJul 29, 2026

Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers

Ritu C. Shah, Alex T. Larsson, Belinda B. Garana…·Sara J.C. Gosline

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

DOI 10.64898/2026.07.28.741264

humanbulk RNA-seq

𝕏 PostBluesky